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Abstract      
We present a case of sub-total cavernous sinus thrombosis secondary to Panton-Valentine 
leucocidin-associated Staphylococcus aureus pyomyositis of the muscles of mastication in a 
previously healthy child, who was successfully managed with no residual disease.  He was 
found to have a factor V Leiden heterozygous mutation.  We highlight the propensity of PVL-
SA to induce venous thrombosis at any site, but with potential for more severe 
consequences in the head.  We raise attention to pyomyositis as a differential for peri-orbital 






A 13-year-old white British male presented with a 5-day history of headaches, malaise and 
unilateral left sided facial swelling followed by pyrexia.  He also reported pain on mastication 
and blurring of left sided vision and his mother reported vague episodes of confusion. He 
had been prescribed co-amoxiclav, ibuprofen and paracetamol by his GP with no clinical 
improvement. There was no history of trauma to the area.  There was a past medical history 
of mild allergic rhinitis but he took no regular medications.  There was no family history of 
immunodeficiency.  On examination the patient was pyrexial with extensive facial and orbital 
tenderness and erythematous swelling, extending from the left forehead to the left temporo-
mandibular joint. Neurological and visual examinations were normal. The left tympanic 
membrane was bulging but without signs of perforation. Cardiovascular, respiratory and 
abdominal examinations were normal. External ocular movements were normal. 
At presentation, the C-reactive protein was 278 mg/L.  Full blood count was normal with 
white count 6.28 x109/L, neutrophils 5.07 x109/L and platelet count 182 x109/L.  A clinical 
diagnosis of peri-orbital cellulitis was made.  The significance of the unusual symptoms of 
pain on mastication was not initially noted by the treating clinicians.  Intravenous ceftriaxone 
and metronidazole were commenced. After forty-eight hours there was no clinical 
improvement.  The patient underwent enhanced CT imaging of the head, facial bones and 
orbit.  The initial imaging findings included opacification of the sphenoid sinus with an air-
fluid level  but no bony erosion. In addition there was an expanded left cavernous sinus 
containing a filling defect associated with a prominent left superior ophthalmic vein in 
keeping with partial left cavernous sinus thrombosis (Figure 1A).  The patient was 
transferred to the local tertiary centre for further management for consideration of drainage 
of the sphenoid collection.  Opinion from otorhinolaryngology was that the sphenoid disease 
was not significant enough to be the source of infection and re-consideration of the CT 
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images identified diffuse thickening of the left temporalis, masseter and pterygoid muscles 
(Figure 1B) with some mild enhancement with formation of small collection around the 
superior and medial aspect of the pterygoid muscles, too small to drain. The significance of 
the pain on mastication and swelling extending to the tempero-mandibular joint was then 
appreciated to be due to facial soft tissue infection.  The concurrent rhinosinusitis was 
considered minor and not the source of infection.  Methicillin-sensitive Staphylococcal 
aureus (MSSA) had been cultured from the blood at the original hospital but blood cultures 
were sterile subsequently by the time of transfer.  Due to response and ease of 
administration, a decision was made to continue ceftriaxone with additional clindamycin in 
place of metronidazole.  It was considered that the source of infection was pyomyositis of the 
facial muscles.  Levels of serum immunoglobulins and nitroblue tetrazolium testing were all 
normal.  HIV test was negative.  Echocardiogram was performed and did not demonstrate 
any cardiac vegetations.  Anticoagulation was initially commenced with dalteparin prior to 
starting warfarin therapy. 
The child improved clinically with intravenous ceftriaxone and oral clarithromycin.  The 
MSSA was typed as Panton-Valentine leucocidin (PVL) positive.  In view of the good 
therapeutic response, antibiotics were not changed.  He was discharged home for ongoing 
antibiotic and anticoagulant therapy in the community.  
Repeat enhanced MR imaging after two months showed significant improvement of muscle 
swelling, decrease in size of the collection but incomplete resolution of the cavernous sinus 
thrombosis. Ceftriaxone had been stopped due to development of a rash attributed to allergy 
to ceftriaxone.  In view of incomplete resolution of the thrombosis and the potential for viable 
bacteria to persist within it, clindamycin was continued for a further two months until a further 
MRI demonstrated resolution of thrombosis and resolution of the swelling of the muscles of 
mastication (Figure 1C-D).  The patient and household members all underwent topical and 
nasal Staphylococcus aureus decolonisation therapy.  Anti-coagulation was continued for a 
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total of six months and followed by a thrombophilia screen.  The only abnormality found was 





Pyomyositis is an acute bacterial infection of skeletal muscle with localized abscess 
formation.  Staphylococcus aureus (SA) accounts for 75%–90% of these infections (ref 
Verma 2016).  Primary pyomyositis is a rare disease, as skeletal muscles are relatively 
resistant to bacterial infections.  However, under certain circumstances, S. aureus can 
invade muscle groups via haematogenous spread.  This usually occurs without evidence of 
spread from a contiguous structure or through a cutaneous portal of entry. 
Although several case studies of pyomyositis in children and adults have been published, 
many of the patients described in the earlier literature had underlying conditions, such as 
immunodeﬁciency or diabetes mellitus (ref Pannaraj CID 2006).   Pyomyositis typically 
occurs in the absence of direct percutaneous inoculation, and is believed to arise through 
haematogenous spread, often amongst those engaged in more exercise and at sites of 
previous minor trauma such as such as those around the hips (ref Unnikrishna Int Orthop 
2010).  , often several days prior to infection becoming apparent. (ref Verma).  In the last 15 
years, reports of SA pyomyositis in temperate climates have increased (ref Unnikrishna). 
Many of these are associated with the production of PVL (PVL-SA) (4).  Whilst there have 
been occasional reports of PVL-SA causing facial cellulitis or cervical lymphadenitis, to our 
knowledge, this is the first report of PVL-SA pyomyositis affecting the face.  Due to its rarity, 
facial soft tissue infection was not considered by the treating clinicians, despite the history of 
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pain on mastication and lateral facial swelling which are not typically seen in peri-orbital or 
orbital cellulitis.  There is a lack of evidence to guide management decisions in PVL-SA (ref 
Ritz PIDJ 2012).  Expert opinion has suggested use of clindamycin and rifampicin to switch 
of toxin production in PVL-SA, such as in UK guidance (ref HPA 2008).  In the case 
presented here, the patient responded quickly to clindamycin alongside ceftriaxone.  It is 
theoretically possible that use of rifampicin or linezolid in addition may have led to more 
rapid resolution.  He received a prolonged treatment course in case of viable bacteria 
surviving within the endovascular thrombosis.  Antimicrobial therapy was stopped once the 
thrombosis had fully resolved. 
Paediatric cavernous sinus thrombosis (CST) is a rare and life-threatening complication of 
septic or aseptic etiologies, and is associated with low morbidity and mortality if aggressive 
therapies including antimicrobials, anticoagulation, and/or surgical treatment are 
implemented early on. CST is associated with neurologic disability if not detected in a timely 
manner. Classic presentations of CST include abrupt onset of unilateral periorbital oedema, 
headache, photophobia and proptosis.  Although, our patient did not have clinical signs 
specific to CST, there was enlargement of the left ophthalmic vein accompanied by a filling 
defect, evidence of a partial occlusion.  Without swift therapy it may have progressed to total 
occlusion. 
There is a greater propensity for S. aureus infections caused by PVL-producing strains to be 
complicated by deep vein thrombosis (DVT).  Facial SA infection is a recognized risk factor 
for CST (ref Desa 2012), with PVL-SA increasing the risk further.  There is general 
consensus that anti-coagulation therapy should be given for DVT in PVL-SA infection (ref 
Ritz PIDJ 2012), with the risk of haemorrhage being outweighed by the benefit of resolving 
current thrombosis and limiting the development of further thrombosis when the endothelium 
and platelets are activated.  For cerebral venous thrombosis (CVT), however, the 
consequences of haemorrhage are highly significant.  Whilst studies are limited and not 
randomized in children, both European (ref Lebas 2012) and British guidelines (ref BSCH) 
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recommend anti-coagulation with LMWH and then vitamin K antagonists for CVT in adults.  
Both guidelines recommend 3 months duration for a transient provocation and six months for 
idiopathic.  The British guideline also recommends this for children, although the European 
guideline is more circumspect stating such therapy as reasonable according to individual 
circumstances.  Given the age of our patient, LMWH was initially commenced, and then 
switched to warfarin.  Resolution of thrombosis took four months, so a total of six months 
anticoagulation was given in this case.   
It is not clear whether the heterozygous factor V Leiden mutation in this patient made a 
significant contribution to thrombosis risk.  Such mutations are common, present in 2-8% of 
Caucasian population (ref: xxx). Individuals with this mutation usually don’t tend to present 
with venous thrombosis until they are adults.  To our knowledge, there is only a single 
previous report of PVL-SA infection causing DVT in association with the heterozygous factor 
V Leiden state, but that patient also had a mutation in the prothrombin gene (ref: An 
uncommon presentation for a severe invasive infection due to methicillin-resistant 
Staphylococcus aureus clone USA300 in Italy: a case report.  Piero Valentini,1 Gabriella 
Parisi,2 Monica Monaco,3 Francesca Crea,1 Teresa Spanu,4 Orazio Ranno,1 Mirella Tronci,2 
and Annalisa Pantosti 3.  We are not aware of studies that have explored whether this 
common mutation actually does increase the risk of DVT risk in PVL-SA infection. 
We have presented a case of sub-total CST following PVL-SA pyomyositis of the left lateral 
pterygoid muscle in a healthy child, who was successfully managed with no residual 
disease.  We highlight the propensity of PVL-SA to induce venous thrombosis at any site, 
but with potential for more severe consequences in the head.  In cases of facial infection, we 
would strongly advocate close examination of imaging to look for evidence of even sub-total 
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Figure 1. (A) Enhanced venous phase CT image showing an expanded left 
cavernous sinus with a convex outer border containing a filling defect (arrow) at 
presentation. (B) Unenhanced coronal CT image showing diffuse swelling of the left 
temporalis muscle and marked asymmetry compared to the contralateral side 
(arrows) at presentation. (C) Enhanced T1-weighted image demonstrating normal 
enhancement of the cavernous sinus with no filling defects (arrow), four months after 
presentation. (D) Unenhanced T1-weighted, coronal image showing resolution of the 
left temporalis muscle swelling (arrows), four months after presentation.  

